Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

Table 1

Platforms of conditioning regimens, GVHD prophylaxis, and graft source.


Reference	Conditioning regimen	GVHD prophylaxis	Graft source

O’Donnell et al., 2002 [24]	FluCyTBI	PTCy D +3, Tac MMF	BM

Luznik et al., 2008 [25]	FluCyTBI	PTCy D +3 ± D +4, Tac MMF	BM

Symons et al., 2011 [26]	BuCy or CyTBI	PTCy, Tac MMF	BM

Brunstein et al., 2011 [27]	FluCyTBI	PTCy, Tac MMF	BM

Pingali et al., 2014 [28]	FluMel Thiotepa or TBI	PTCy, Tac MMF	BM (94%)

Solomon et al., 2012 [29]	FluBuCy	PTCy, Tac MMF	PBSC

Raiola et al., 2013 [30]	FluBu Thiotepa () FluTBI 9.9 Gy ()	PTCy, CsA MMF	BM

Raj et al., 2014 [31]	FluCyTBI	PTCy, Tac MMF	PBSC

Bhamidipati et al., 2014 [32]	FluCyTBI	PTCy, Tac MMF	PBSC

Castagna et al., 2014 [33]	BM FluCyTBI	PTCy, Tac MMF 74% PTCy, CsA MMF 26%	BM (67%)
Castagna et al., 2014 [33]	PBSC FluCyTBI	PTCy, Tac MMF	PBSC (33%)

Solomon et al., 2015 [34]	Flu/TBI (12 Gy)	PTCy, Tac MMF	PBSC

Bradstock et al., 2015 [35]	BM FluCyTBI	BM PTCy D +3, Tac MMF	BM
Bradstock et al., 2015 [35]	PBSC FluCyTBI	PBSC PTCy D +3 D +4, Tac MMF	PBSC

Gayoso et al., 2013 [36]	NMA 77.5% MA 22.5%	PTCy, CNI, MMF	BM 51% PBSC 49%

Sugita et al., 2015 [37]	FluCyBuTBI	PTCy, Tac MMF	PBSC

BM, bone marrow; Bu, busulfan; CsA, cyclosporine; CNI, calcineurin inhibitor; Cy, cyclophosphamide; D, day; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate; PTCy, posttransplant cyclophosphamide; Tac, tacrolimus; TBI, total body irradiation; PBSC, peripheral blood stem cells.

Advances in Hematology

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

Table 1